Temozolomide and oral etoposide in children with recurrent malignant brain tumors

Temozolomide and oral etoposide in children with recurrent malignant brain tumors

Despite advances in the treatment of brain tumors, the prognosis of children with recurrent malignant brain tumors remains poor. Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors. Its efficacy appears schedule dependent...

Full description

Bibliographic Details
Main Authors: Antonio Ruggiero, Anna Ariano, Silvia Triarico, Michele Antonio Capozza, Alberto Romano, Palma Maurizi, Stefano Mastrangelo, Giorgio Attinà
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-06-01
Series:Drugs in Context
Subjects:
etoposide
glioma
medulloblastoma
recurrent brain tumor
temozolomide
Online Access:https://www.drugsincontext.com/temozolomide-and-oral-etoposide-in-children-with-recurrent-malignant-brain-tumors

Internet

https://www.drugsincontext.com/temozolomide-and-oral-etoposide-in-children-with-recurrent-malignant-brain-tumors

Similar Items